Pharming Group N.V.
PHGUF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $297,200 | $245,316 | $205,622 | $189,853 |
| % Growth | 21.1% | 19.3% | 8.3% | – |
| Cost of Goods Sold | $35,399 | $25,212 | $17,562 | $20,183 |
| Gross Profit | $239,986 | $220,104 | $186,928 | $169,670 |
| % Margin | 80.7% | 89.7% | 90.9% | 89.4% |
| R&D Expenses | $83,147 | $68,914 | $52,531 | $67,178 |
| G&A Expenses | $92,081 | $80,684 | $62,443 | $35,297 |
| SG&A Expenses | $99,216 | $87,501 | $68,853 | $92,047 |
| Sales & Mktg Exp. | $7,135 | $6,817 | $6,410 | $56,750 |
| Other Operating Expenses | $61,131 | $69,076 | $48,443 | -$2,502 |
| Operating Expenses | $243,494 | $225,491 | $169,827 | $156,723 |
| Operating Income | -$3,508 | -$5,387 | $18,233 | $27,839 |
| % Margin | -1.2% | -2.2% | 8.9% | 14.7% |
| Other Income/Exp. Net | $129 | -$6,625 | -$3,246 | -$4,761 |
| Pre-Tax Income | -$8,492 | -$12,012 | $14,987 | $22,032 |
| Tax Expense | $3,349 | -$1,464 | $1,313 | $6,760 |
| Net Income | -$11,332 | -$10,769 | $13,674 | $15,996 |
| % Margin | -3.8% | -4.4% | 6.7% | 8.4% |
| EPS | -0.017 | -0.015 | 0.021 | 0.025 |
| % Growth | -12.7% | -171.4% | -16% | – |
| EPS Diluted | -0.017 | -0.015 | 0.019 | 0.023 |
| Weighted Avg Shares Out | 687,750 | 674,600 | 651,143 | 695,509 |
| Weighted Avg Shares Out Dil | 687,750 | 674,600 | 719,684 | 701,152 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,649 | $3,529 | $87 | $51 |
| Interest Expense | $9,517 | $5,964 | $5,563 | $5,948 |
| Depreciation & Amortization | $10,568 | $15,925 | $13,188 | $19,610 |
| EBITDA | $13,642 | $9,877 | $33,533 | $48,779 |
| % Margin | 4.6% | 4% | 16.3% | 25.7% |